LIXTE Biotechnology Reports First-Quarter Progress on Oncology Pipeline and Strategic Expansion

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its first-quarter 2026 Form 10-Q, highlighting continued advancement of its lead oncology candidate, LB-100. The company reported expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. LIXTE also cited continued growth at its recently acquired Liora Technologies Europe subsidiary as it pursues broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT. This announcement underscores LIXTE's commitment to advancing its oncology pipeline and expanding its capabilities through strategic acquisitions, positioning the company for potential growth in the cancer treatment landscape.